NeoDynamics restarts patient recruitment to UK COMPULSE Study to optimize diagnosis of breast cancer
STOCKHOLM - July 6, 2020. NeoDynamics AB (Spotlight Stock Market: NEOD), announces that the Company restarts patient recruitment to the UK COMPULSE Study following a temporary pause imposed by the COVID-19 pandemic.COMPULSE is a comparative study to investigate the potential benefits of NeoNavia, the first pulse biopsy system, compared to current standard of practice. It is a follow-on study derived from the ongoing German PULSE study. Patient recruitment has restarted in selected UK hospitals. The first hospitals to recruit patients are the Nightingale Centre in Manchester and Addenbrookes